J Stroke.  2021 May;23(2):147-148. 10.5853/jos.2021.01690.

Patent Foramen Ovale Closure: Opportunity Closed in Old Patients?

• Kim JS
• Hong KS

• KMID: 2516405
• DOI: http://doi.org/10.5853/jos.2021.01690

Reference

References

1. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013; 368:1092–1100.

2. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017; 377:1011–1021.

3. Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017; 377:1033–1042.

4. Messé SR, Gronseth GS, Kent DM, Kizer JR, Homma S, Rosterman L, et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020; 94:876–885.

5. Köhrmann M, Schellinger PD, Tsivgoulis G, Steiner T. Patent foramen ovale: story closed? J Stroke. 2019; 21:23–30.

6. Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013; 81:619–625.

7. Mazzucco S, Li L, Rothwell PM. Prognosis of cryptogenic stroke with patent foramen ovale at older ages and implications for trials: a population-based study and systematic review. JAMA Neurol. 2020; 77:1279–1287.

8. Kwon H, Lee PH, Song JK, Kwon SU, Kang DW, Kim JS. Patent foramen ovale closure in old stroke patients: a subgroup analysis of the DEFENSE-PFO trial. J Stroke. 2021; 23:289–292.